AstraZeneca has announced its ambition to have zero carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon negative by 2030, bringing forward decarbon
W2O has bought US-based advertising and medical education 21GRAMS, expanding its direct-to-consumer, direct-to-provider and business-to-business advertising and marketing operations.
OPEN Health has launched a new specialist Learning & Development (L&D) team that will further expand its existing internal training offerings in the pharmaceutical industry.
Biopharma services company Syneos Health has taken a minority stake in Indegene Omnipresence, a partnership between life sciences services company Indegene and software giant Microsoft.
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.